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Radionuclide imaging technologies
Two major technologies that employ radioactive isotopes
(Supplementary Table 1) for imaging molecular events cur-
rently exist: SPECT (carried out with a gamma camera),
employing isotopes in which a single high energy photon is
directly emitted [1]; and PET, in which a positron is emitted
from the radioactive isotope [2]. For positron imaging,
positrons are emitted from nuclei of proton-rich isotopes,
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Abstract
A variety of imaging technologies is being investigated as tools for studying gene expression in living
subjects. Two technologies that use radiolabeled isotopes are single photon emission computed
tomography (SPECT) and positron emission tomography (PET). A relatively high sensitivity, a full
quantitative tomographic capability, and the ability to extend small animal imaging assays directly into
human applications characterize radionuclide approaches. Various radiolabeled probes (tracers) can be
synthesized to target specific molecules present in breast cancer cells. These include antibodies or
ligands to target cell surface receptors, substrates for intracellular enzymes, antisense
oligodeoxynucleotide probes for targeting mRNA, probes for targeting intracellular receptors, and
probes for genes transferred into the cell. We briefly discuss each of these imaging approaches and
focus in detail on imaging reporter genes. In a PET reporter gene system for in vivo reporter gene
imaging, the protein products of the reporter genes sequester positron emitting reporter probes. PET
subsequently measures the PET reporter gene dependent sequestration of the PET reporter probe in
living animals. We describe and review reporter gene approaches using the herpes simplex type 1 virus
thymidine kinase and the dopamine type 2 receptor genes. Application of the reporter gene approach to
animal models for breast cancer is discussed. Prospects for future applications of the transgene
imaging technology in human gene therapy are also discussed. Both SPECT and PET provide unique
opportunities to study animal models of breast cancer with direct application to human imaging.
Continued development of new technology, probes and assays should help in the better understanding
of basic breast cancer biology and in the improved management of breast cancer patients.
Keywords: animal models, imaging, microPET, positron emission tomography, single photon emission computed
tomography
Received: 14 November 2000
Revisions requested: 22 November 2000
Revisions received: 23 November 2000
Accepted: 23 November 2000
Published: 11 December 2000
Breast Cancer Res 2001, 3:28–35
This article may contain supplementary data which can only be found
online at http://breast-cancer-research.com/content/3/1/028
© BioMed Central Ltd on behalf of the copyright holder
(Print ISSN 1465-5411; Online ISSN 1465-542X)Available online http://breast-cancer-research.com/content/3/1/028
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
and eventually interact with electrons. Annihilation occurs,
and the mass of the electron and positron is converted into
two gamma rays that travel outward from the site of annihi-
lation at ~180° to one another. Scintillation crystals com-
posed of different materials are used to capture the gamma
rays for both SPECT and PET. The collection of many
events allows reconstruction of the source of the emissions
(Supplementary Figure 1). PET data can be corrected for
attenuation, which occurs because some of the gamma
rays do not traverse through all of the surrounding tissue.
SPECT data is more difficult to correct for attenuation
effects. PET is about 10-fold more sensitive than SPECT,
primarily because the SPECT cameras use collimators that
reject many of the counts from the source [3]. There are
dedicated breast PET imaging systems under development
[4] that may prove to be clinically important for breast
and/or axillary imaging with improved resolution and/or
sensitivity. We have recently developed microPET technol-
ogy at UCLA, which allows high resolution (~2 mm in each
axial direction) imaging of small animals such as mice [5]
(Supplementary Figure 2).
Although the focus of this review is on radionuclide
imaging technologies, it is worth briefly reviewing other
imaging modalities and how they contrast to PET and
SPECT. Magnetic resonance imaging (MRI) [6] and com-
puted tomography (CT) [7] provide high resolution anatom-
ical imaging that is not available through SPECT and PET.
Development of new contrast agents for MRI is allowing
the study of molecular events, but these approaches are
still in the early developmental stage [8]. Magnetic reso-
nance spectroscopy has also extensively been studied and
is reviewed in detail elsewhere [9]. Optical approaches for
imaging living small animals have been significantly aided
by the use of green fluorescent protein [10] and firefly
luciferase [11]. The use of highly sensitive charge-coupled
device cameras has provided the ability to detect very low
levels of light coming from deep within a living animal. This
approach does not produce tomographic images, but pro-
vides a rapid, low cost method to detect molecular events
using an optical reporter gene.
The advantages of radionuclide technologies and, espe-
cially, PET include high sensitivity (~10–11 M), which
allows for detecting low levels of probes accumulated at a
given site. Furthermore, because the isotopes available for
PET can substitute for naturally occurring atoms in organic
molecules, enormous versatility in the study of biochem-
istry in vivo is possible. The radionuclide approaches do
suffer from a lack of anatomical information that can be
provided by the other technologies. Multiple efforts are
currently underway to build combined MRI/PET and
CT/PET systems [12]. We are performing microPET
studies in our laboratories and are starting to use micro-
CAT technology (Imtek Inc, Knoxville, TN, USA) [13] to
obtain partially registered anatomical information. Clinical
scanners that combine CT and PET have also recently
become available and should help to improve overall diag-
nostic capability [14].
Radionuclide imaging probes
A key advantage of the radionuclide imaging technologies
over other imaging approaches is the ability to label
almost any chemical species with an isotope of choice.
This has allowed the development of hundreds of radio-
active imaging probes capable of imaging a variety of mol-
ecular events [2,15].
A potentially useful way to discuss the general categories
of probes is to start from targets at the cell membrane and
to move to targets within the cell. Two major approaches
are available for those genes that lead to expression of a
protein on the cell surface. These involve antibodies or
antibody fragments to target a specific protein, and spe-
cific ligands to target receptors on cells.
Antibody fragments are being engineered to achieve rapid
targeting and rapid blood clearance [16]. A recent example
from our laboratories of an antibody fragment approach tar-
geting carcinoembryonic antigen expression in a mouse
tumor xenograft model imaged in microPET is shown in
Figure 1. The antibody fragment in this case is labeled with
64Cu, which has a half-life of approximately 12 h. It is likely
that engineered antibody fragments will provide methods
to target many cell surface targets and should continue to
be a general class of radiolabeled imaging probe.
Many possibilities for imaging molecular targets exist as
one considers targets within a cell. Substrates that are
trapped within the cell because they are metabolized by
intracellular enzymes can be exploited for imaging pur-
poses. A specific example of this approach is the widely
used 2-[18F]-2-fluoro-deoxyglucose (FDG) [15,17], which
is actively transported into cells by a glucose membrane
transporter. After hexokinase-mediated phosphorylation,
phosphorylated FDG (FDG-6-PO4) cannot be further
metabolized in the glucose metabolic pathway and is not
able to leave the cell, leading to intracellular trapping of the
radiolabeled compound [2,15] Breast carcinomas, like
many cancers, show noticeable increased glucose metabo-
lism, leading to a pronounced intracellular accumulation of
FDG relative to surrounding tissues. FDG-PET can provide
helpful information in the multimodality evaluation of breast
lesions, therapy response and extent of metastatic disease.
The inability to detect very small tumors (<4 mm diameter)
and the varying metabolic activity of the different tumor
subtypes in breast cancer [18] cause some limitations.
[11C]-Methionine, a proliferation marker capable of detecting
changes in the amino acid metabolism of tumors, might have
an impact in predicting treatment response, but at present
very little data in breast cancer patients are available [19].Breast Cancer Research    Vol 3 No 1 Berger and Gambhir
In vivo imaging of intracellular receptors has also been
reported. The growth of breast epithelial cells is an estro-
gen-mediated process that depends on estrogen acting
through an estrogen receptor (ER) and results in the
induction of progestin receptor. The assay of the levels
of these two receptors is important because it is consid-
ered indicative of the responsiveness of a tumor to hor-
monal agents [20]. The ER content of breast carcinomas
is also known to be an important prognostic indicator.
Successful research has focused mainly on imaging of
estrogen receptors. [18F]-Fluoro-17b-estradiol has high
affinity for the ER, and an excellent correlation has been
noted between the tumoral uptake of this estradiol on
PET images and the tumor ER concentration measured
in vitro [21].
Another important approach that is still in its infancy is the
use of small (15–20 bases) antisense oligodeoxynu-
cleotides that target gene expression by specific hybridiza-
tion to mRNA (Fig. 2). The basis for this approach is rooted
in the use of antisense drugs as methods to inhibit transla-
tion of mRNA [22]. The ability to image endogenous gene
expression using a wide array of radiolabeled probes is
quite a general and powerful approach. The rate-limiting
step, however, is the ability to radiolabel a specific mole-
cule and not to significantly alter its properties. It would be
ideal if there could be a single universal probe that could
image a wide variety of molecular events. The antibody
fragment approach may satisfy this need for cell membrane
targets but not intracellular targets. The antisense
approach with mRNA targeting is a potential general
approach, but it is currently limited and not likely to image
genes with relatively low levels of transcription. If one is
able to introduce an imaging or reporter gene into a group
of cells, imaging gene expression with a universal probe
becomes possible. Several reporter gene approaches for
imaging transferred gene expression, including applica-
tions to gene therapy models, are now discussed.
Principles of imaging reporter gene expression
Molecular biologists have long used reporter genes to
study promoter/regulatory elements involved in gene
expression, inducible promoters to examine the transduc-
tion of gene expression, and transgenes containing
endogenous promoters fused to a reporter gene to study
endogenous gene expression. This is a highly general
Figure 1
MicroPET imaging of a mouse using a [64Cu]-labeled antibody fragment
targeted against carcinoembryonic antigen (CEA) in a xenograft model.
The mouse carried a C6 glioma xenograft on the left shoulder (negative
control) and a LS174T xenograft expressing CEA on the right shoulder
(arrows). The mouse was injected with 26 mCi 64Cu-anti-CEA minibody
and imaged at 5 h, with the highest retention in the LS174T tumor
(arrow) and liver, and lower retention in the control tumor (arrowhead).
The liver signal occurs due to metabolism of the antibody fragment at
that site. 
Figure 2
Illustration of antisense hybridization imaging approach. Small
radioactive antisense oligodeoxynucleotides (RASONs) are used to
target a small portion of a chosen mRNA. If sufficient levels of mRNA
are present, it may be possible to retain the RASONs only in those
cells expressing the mRNA. Efflux would occur in other cells if non-
specific interactions can be minimized. Because radiolabeling
chemistry can be made independent of the RASON sequence, many
different types of mRNA can potentially be targeted.approach because any promoter can be fused to a reporter
gene, and detection of a reporter gene product is a way of
‘indirectly’ following the expression of the gene that the
chosen promoter normally regulates. Once a reporter gene
driven by a promoter of choice is introduced into the
desired tissue, expression of the reporter gene can be
monitored by several conventional methods like tissue
biopsy, followed by immunohistochemistry. Conventional
methods to detect reporter gene expression are, however,
limited by their inability to determine ‘non-invasively’ the
locations and magnitude of gene expression in living sub-
jects over time. Approaches using green fluorescent
protein [10] and firefly luciferase [11] as reporter genes
allow localization of reporter gene expression in some living
animals, but monitoring of the detailed location and magni-
tude of reporter gene expression over time is difficult.
Approaches using MRI are reviewed elsewhere [8].
Radionuclide imaging techniques offer the possibility of
monitoring the detailed location, magnitude, and time varia-
tion of reporter gene expression with high sensitivity for in
vivo use in animals and humans [23]. A promoter of choice
drives transcription of a reporter gene. The accumulation of
the reporter probe is dependent directly on the expression
of the reporter gene: the translation of the reporter gene
mRNA leads to a protein product that can interact with a
reporter probe. This interaction may be based on uptake
and enzymatic conversion of the reporter probe via the
reporter protein, leading to retention of the metabolite(s) or
a receptor ligand based interaction (Fig. 3).
The choice of a promoter for driving reporter gene expres-
sion depends on the intended application. Constitutive
promoters can be used to produce continuous transcrip-
tion of the reporter gene. Inducible promoters can be used
to provide external control for varying the levels of tran-
scription. To mimic the transcription of some endogenous
gene, one can use the identical promoter of the endoge-
nous gene to be imaged. This allows the use of reporter
genes to indirectly monitor the expression of an endoge-
nous gene. Two reporter gene approaches are discussed:
the herpes simplex type 1 virus thymidine kinase
(HSV1-tk) and the dopamine type 2 receptor (D2R). Other
approaches have also been developed and are reviewed
elsewhere [24,25].
The  HSV1-tk gene (HSV1-TK is the corresponding
enzyme) has its roots in a therapeutic approach as a
‘suicide gene’ [25,26]. HSV1-TK, like murine and human
TK, phosphorylates thymidine. HSV1-TK, however, phos-
phorylates acycloguanosines (eg acyclovir, ganciclovir,
penciclovir) much more effectively than do mammalian
TKs. Cellular enzymes then convert the acycloguanosine
monophosphates to diphosphates and triphosphates that,
if present in sufficient concentration, kill cells by incorpora-
tion as chain-terminating derivatives or by direct inhibition
of DNA polymerase. Because HSV1-TK converts acy-
cloguanosine prodrugs to toxic compounds, this approach
is used in cancer gene therapy protocols as a suicide
gene approach [26]. The actual approach is to deliver the
HSV1-tk gene to tumor cells, then use acycloguanosines
to kill the cells expressing HSV1-tk. The relaxed substrate
specificity by the viral TK is critical in the approach of
HSV1-tk suicide gene therapy, but can also be exploited
using the HSV1-tk gene in an imaging approach.
Two main categories of substrates, uracil nucleoside
derivatives and acycloguanosine derivatives, have been
investigated specifically as reporter probes for imaging
HSV1-tk reporter gene expression for SPECT and PET.
These reporter probes are transported into cells, and
trapped as a result of enzymatic phosphorylation by
HSV1-TK. The choice of acycloguanosine derivatives (eg
ganciclovir) as potential reporter probes was based on
their ability to be radiolabeled with 18F, which has several
ideal characteristics as an isotope [27]. The reporter
probe is only used in tracer doses (not in pharmacological
doses as in suicide therapy), so there are no known prob-
lems concerning cell toxicity.
8-[18F]-Fluoroganciclovir has been validated as a reporter
probe for HSV1-tk gene expression using a replication-
deficient adenovirus, Ad-CMV-HSV1-tk, encoding HSV1-tk
Available online http://breast-cancer-research.com/content/3/1/028
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Figure 3
Schematic illustrating a reporter gene approach. An imaging reporter
gene has to be introduced into the cell, which is driven by a promoter of
choice. Transcription of the imaging reporter gene with subsequent
translation of the mRNA leads to an enzyme. This enzyme can selectively
trap an imaging reporter probe. The imaging reporter probe will not be
trapped in those cells in which there is no expression of the imaging
reporter gene. Note that it is also possible for the imaging reporter gene
to encode for an intracellular and/or cell surface receptor. This receptor
would then bind the imaging reporter probe (a ligand). Levels of the
trapped probe can be related to levels of imaging reporter gene
expression in either approach. expressed under the control of the CMV promoter [28].
Other laboratories are also developing positron-labeled
substrates to image the HSV1-tk PET reporter gene in
living animals [29]. Radioactive 5-iodo-2¢-fluoro-2¢-deoxy-1-
b-D-arabinofuranosyl-5-ioduracil (FIAU) has been used to
image stable HSV1-tk gene expression in transplanted
tumors and HSV1-tk genes delivered in retroviral vectors to
transplanted tumors. Using [124I]-labeled FIAU, data similar
to that observed with 8-[18F]-fluoroganciclovir and 8-[18F]-
fluoropenciclovir were obtained in imaging HSV1-tk
expression in tumors by PET. Because of its longer half-life
(4 days), [124I]-FIAU may be a useful alternative to image
HSV1-tk in some applications in which the background
signal needs to be minimized. FIAU can additionally be
labeled with single photon emitting iodine, allowing direct
imaging with SPECT [30]. Further details of the HSV1-tk
reporter gene system and various reporter probes are
reviewed elsewhere [25]. We have also recently studied a
mutant HSV1-sr39tk reporter gene with a better sensitivity
for detecting lower levels of reporter gene expression [31].
Figure 4 presents an example of repetitive microPET
imaging of a mutant HSV1-sr39tk reporter gene using a
[18F]-labeled penciclovir molecule. An adenoviral vector is
used to deliver the HSV1-sr39tk reporter gene to the liver.
The adenoviral vector targets the liver because of Cox-
sackie adenoviral receptors present on hepatocytes.
[18F]-Fluoroethylspiperone (FESP) is a positron-labeled
analog of the dopamine antagonist spiperone. This tracer
was developed to evaluate the level of D2R in vivo in
animals and humans [32]. Endogenous high level D2R
expression is limited primarily to the striatum. We have
used the D2R gene as a reporter gene and FESP as a
reporter probe for imaging gene expression [33]. There is
no pharmacological effect of FESP in cells ectopically
expressing D2R when FESP is used in small tracer con-
centrations like in PET imaging. Imaging of both the
HSV1-tk and D2R reporter genes in animal models of
tumor xenografts had been already successfully performed
by our laboratories (Supplementary Figure 3) [34]. Further
comparisons of the HSV1-tk and D2R reporter gene
systems are provided elsewhere [25].
Potential applications of the reporter gene technologies
developed for the study of breast cancer models are
numerous. It should now be possible to mark any breast
cancer cell line with a reporter gene for subsequent
imaging of cell trafficking in living animals. Stable transfec-
tion of the reporter gene into a given cell line is possible
using plasmids carrying the reporter gene, and antibiotic
selection markers or viral vectors with subsequent selec-
tion of cell lines stably expressing the reporter gene. Once
available, these cells can be directly implanted to study
cell growth and trafficking with or without pharmacological
intervention. Several models are now under study in which
breast cancer metastases can be monitored non-invasively
over time. Transgenic mice can also be developed in
which a breast tissue specific promoter drives the reporter
gene. This allows the study of spontaneous tumors as they
develop and metastasize. The reporter genes also provide
a unique way to optimize gene therapy through tracking
the delivered genes, and are now discussed in detail.
Gene therapy applications
Several gene therapeutic approaches to breast cancer
treatment have been considered. A very important strategy
is the attempt to correct or compensate specific genetic
defects in breast cancer cells. Such efforts to compensate
mutations include ablation of oncogenic products, restora-
tion of receptor expression (eg estrogen receptor expres-
sion), alteration of genes involved in the induction of
apoptosis, or activation of tumor suppressor genes
[35,36]. Mutations in the p53 gene are among the very
Breast Cancer Research    Vol 3 No 1 Berger and Gambhir
Figure 4
Adenoviral-mediated HSV1-sr39tk gene expression repetitively imaged
in two mice. Each mouse was tail-vein injected with 1.0 × 109 pfu
adenovirus in which the HSV1-sr39tk reporter gene is driven by the
CMV promoter. Each mouse was imaged in a microPET system at the
days indicated 1 h after tail-vein injection of 250 mCi [18F]-labeled
penciclovir molecule (FHBG). The scale represents the accumulation
of FHBG measured as percent injected dose per gram of tissue
(%ID/g). (a) The Swiss Webster mouse shows a decrease in gene
expression over time, and (b) the nude mouse shows persistence of
gene expression in the liver. These differences are likely due to the
immune system being fully competent in the Swiss Webster mouse.Available online http://breast-cancer-research.com/content/3/1/028
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common changes in breast cancer [37]. Wild type p53
functions as a tumor suppressor gene in breast cancer
cells, as shown by the growth suppression of cells in vitro
when transfected with wild type expression vectors [38].
Retroviral delivery of wild type p53 into human breast
cancer cells suppresses tumorigenicity in nude mice [38].
Hung et al [39] developed a phase I clinical trial of E1A
gene therapy targeting Her-2/neu overexpressing breast
and ovarian cancer. HER2/neu overexpression in breast
cancer is considered linked with lower response to
chemotherapy and unfavorable prognosis. This group
identified a viral transcriptional regulator, the adenovirus
type 5 E1A, that can repress HER-2/neu overexpression.
Expression of E1A in HER-2/neu overexpressing cancer
cells resulted in downregulation of HER-2/neu in vitro,
which reversed the malignant phenotype and restored
sensitivity to chemotherapeutic agents. Preclinical in vivo
studies showed that the E1A gene was able to function
therapeutically as a tumor suppressor gene in breast
cancer xenograft models. In the phase I clinical trial, Hung
et al showed that the E1A gene can be delivered to
cancer cells by a cationic liposomal delivery system. HER-
2/neu  was downregulated and the E1A gene induced
apoptosis. A general drawback of the mutation compensa-
tion approach is that transfection of most of the tumor
cells is needed to obtain a clinical effect, because intracel-
lular responses are being modulated without effect on sur-
rounding non-transfected cells.
Approaches such as molecular chemotherapy (shows a
regional ‘bystander effect’) or immune therapy (has the
potential to generate a systemic response) hold even
more promise for becoming the breast cancer therapies of
the future [35]. Molecular chemotherapy aims to increase
the sensitivity of the tumor cells to chemotherapy or to find
more specific ways of drug delivery to tumor cells [40].
The most studied system to accomplish cell killing uses
the already discussed TK gene from the herpes simplex
virus and gangiclovir as a prodrug.
Tumor specificity of molecular chemotherapy can be
enhanced through the use of transductional or transcrip-
tional targeting. Transductional targeting directs viral gene
delivery vectors specifically to tumor cells, which express
unique epitopes like erbB2 or the mucin protein core.
Transcriptional targeting may be accomplished through
the use of breast or tumor specific promoters such as
Muc-1, HER-2, Myc and others [40].
Imaging modalities to verify the location, magnitude and
duration of transgene expression are highly recommended
in all these approaches, and will be very useful in attempts
to optimize gene therapy protocols in general and time of
prodrug application in particular.
A third strategy, genetic immunotherapy [35], aims to
augment the specificity and magnitude of the immune
response against tumor-associated antigens. These thera-
pies include passive and active immunization, introduction
of cytokines, and expression of T cell costimulatory mol-
ecules [36]. An advantage of this approach is not having
to introduce the therapeutic gene into all metastatic sites.
The use of cytokines for immunotherapy has been limited
by the toxicities associated with systemic administration of
the proteins. Recombinant adenoviral vectors containing
various cytokine genes have been used to deliver high
local concentrations of the cytokines intratumorally. In a
subcutaneous model of metastatic breast cancer in trans-
genic mice, direct intratumoral injection of an adenoviral
vector expressing IL-12 resulted in tumor regression in
75% of the treated animals [41]. Adenoviral-mediated
gene delivery of IL-2 was recently evaluated in a phase I
clinical trial in metastatic breast cancer and melanoma
patients, showing the safety of this approach [42].
Given the magnitude of breast cancer as a clinical
problem, however, few gene therapy clinical trials have
until now been initiated. The exceptional heterogeneous
molecular biology of this cancer, production of immuno-
suppressive factors, and the widespread nature of the
disease are three examples of the difficulties faced in
breast cancer gene therapy [36]. Recent advances in
understanding the molecular cell biology underlying breast
cancer nevertheless revealed several potentially clinically
useful gene therapy approaches for the near future.
Non-invasive imaging of transgene expression will be of
great benefit in assessing organ tissue specificity as well
as level and duration of transgene expression in vivo, and
could therefore be very useful in validation of new delivery
systems as well as in monitoring clinical gene therapy
trials. Most therapeutic transgenes do not lend themselves
to direct imaging of the transgene product. Most thera-
peutic transgene products lack appropriate ligands or
probes that can be radiolabeled and used to generate
images that define the magnitude of transgene expression.
It would also be very difficult to develop and validate new
ligands and probes for each therapeutic transgene. Alter-
natively, it is reasonable to develop and validate indirect
imaging strategies using a reporter gene in combination
with a therapeutic gene.
Three strategies can potentially be used for imaging gene
expression for gene therapy [25]. One strategy uses a
fusion gene containing cDNA from both the reporter and
therapeutic gene. The second strategy uses a cis-linked
reporter gene in which a single mRNA is transcribed from
both genes [43]. In the final strategy, the same amount of
two separate vectors can be injected. One vector is used
to transfer the therapeutic gene, and the second delivers
the reporter gene. The injected vectors are identical apartfrom this genetic difference, and the same promoter drives
both genes. The expression of the reporter gene reflects,
at the macroscopic tissue level, at least in some diagnos-
tic situations, the expression of the therapeutic gene [44].
All three strategies are based on demonstrating a propor-
tional and constant relationship in the coexpression of two
transgenes over a wide range of expression levels. The
advantage of these paradigms is that they can potentially
be applied to any gene combination. Strict coexpression
of two proteins in equimolar amounts can only be
achieved by a fusion gene encoding both gene products.
However, fusion proteins may not yield functional activity,
may not localize in the appropriate subcellular compart-
ment, or may induce immunogenic reactions; therefore,
this approach is not ideal for in vivo studies. The propor-
tional expression of two cis-linked genes is possible using
an internal ribosomal entry sites (IRES) element within a
single bicistronic transcription unit. The IRES element
enables translation initiation within the bicistronic mRNA,
thus permitting gene coexpression by cap-dependent
translation of the first cistron and cap-independent, IRES-
mediated translation of the second cistron. It will eventu-
ally be important to assess whether IRES-based vectors
are reliable indicators of transgene coexpression in differ-
ent tissues, taking into account the half-life of each
encoded protein. Whether the genes located upstream
and downstream are equally expressed for a given appli-
cation also has to be investigated. An example of using a
bicistronic system to image gene expression in a tumor
model is available elsewhere (Supplementary Figure 4)
[43]. This work should help form the basis for extending
this approach into gene therapy trials.
Future prospects
The future potential of radionuclide assays with SPECT and,
particularly, PET imaging is quite promising. As small animal
imaging technologies continue to spread to major research
centers and the development of general probes expands,
animal research should be significantly accelerated. The
study of breast cancer cell trafficking and basic tumor
biology in xenograft and transgenic models should be possi-
ble. Optimization of gene therapy should also be possible.
The results from animal models should be rapidly translated
into human applications because of a rapidly growing base
of imaging scanners, which should lead to improved diagno-
sis and management of breast cancer patients.
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Supplementary Table 1
Radionuclides of interest for positron emission tomography
(PET) and single photon emission computed tomography
(SPECT) studies
Radionuclide Half-life Type
11C 20.3 min PET
13N 9.97 min PET
15O 122 s PET
18F 109.8 min PET
62Cu 9.74 min PET
64Cu 12.7 h PET
68Ga 68.1 min PET
76Br 16.1 h PET
124I 4.17 days PET
131I 8.0 days SPECT
123I 13.2 h SPECT
111In 2.8 days SPECT
67Ga 78.3 h SPECT
99mTc 6.0 h SPECT
201Tl 73.1 h SPECT
127Xe 36 days SPECT
133Xe 5.2 days SPECTBreast Cancer Research    Vol 3 No 1 Berger and Gambhir
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Supplementary Figure 1
Schematic illustrating single photon emission computed tomography
(SPECT) and positron emission tomography (PET). (a) In SPECT, a
single photon is produced as the isotope decays and this single
photon must be detected through rotating detectors using a collimator.
(b) In PET, annihilation eventually occurs with the positron and
electron to produce two high energy (511 keV) gamma rays at ~180°
that are detected using a circular ring of detectors.
Supplementary Figure 2
Photograph of the microPET scanner designed at UCLA, Los Angeles,
CA, USA. The scanner is capable of imaging small animals such as
mice in 30–60 min with a spatial resolution of ~2 mm in each axis (8
mm3). The scanner uses an 8 × 8 array of 2 × 2 × 10 mm3 lutetium
oxyorthosilicate crystals. The ring diameter is 17.1 cm. The transaxial
and axial fields of view are 17.1 and 1.8 cm, respectively.
Supplementary Figure 3
Imaging of two reporter genes in the same mouse. A nude mouse
carrying two tumors (left, dopamine 2 receptor [D2R]; right, herpes
simplex virus type 1 thymidine kinase [HSV1-tk]) was imaged in a
microPET system with tail-vein injection of ~250 mCi [18F]-
fluoroethylspiperone (FESP) and, 24 hours later, with ~250 mCi 8-
[18F]-fluoropenciclovir (FPCV). Imaging began 1 hour after injection of
each tracer. These results show the ability to image both the D2R and
the HSV1-tk reporter genes in the same living mouse with microPET.
The scale represents the accumulation of FESP and FPCV measured
as percent injected dose per gram of tissue (%ID/g).
Supplementary Figure 4
Imaging bicistronic gene expression. MicroPET imaging of the pCMV-
D2R-IRES-tkm C6 tumors in a nude mouse. Three C6 cell lines stably
transfected with pCMV-D2R-IRES-sr39tk (labeled A, B, C) and the C6
parental cell line (labeled D) were injected into four separate sites in a
single mouse. After 10 days, when each tumor was at least 6 mm in
diameter, the mouse was imaged with 2-[18F]-2-fluoro-deoxyglucose
(FDG), followed 24 h later with [18F]-fluoroethylspiperone (FESP),
followed 24 h later with 8-[18F]-fluoropenciclovir (FPCV). The FDG
(whole body) image represents the average of all coronal (horizontal)
planes and therefore the four tumors are not well visualized. The FDG
(section) image taken from a set of planar images passing through all
four tumors shows accumulation of FDG in all four tumors. Correlated
signal intensity is observed between the FESP and FPCV images for
each tumor. There is a high correlation between FESP and FPCV
microPET signals. Br, Brain; Bl, bladder; R, rectum; %ID/g, percent
injected dose per gram of tissue.